Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price decrease of -10.06%. However, over the past six months, we’ve seen a stronger performance of -38.36%. The price of CRBU leaped by -11.18% over the last 30 days. And in the last five days, it has fallen by -5.30%.
Caribou Biosciences Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $8.33 on 02/28/24 and a low of $1.30 for the same time frame on 01/30/25.
52-week price history of CRBU Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Caribou Biosciences Inc’s current trading price is -82.83% away from its 52-week high, while its distance from the 52-week low is 10.00%. The stock’s price range during this time has been between $1.30 and $8.33. The trading volume for the Healthcare sector company’s shares reached about 3.67 million for the day, which was higher than the average daily volume of 1.64 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Caribou Biosciences Inc (CRBU) has experienced a quarterly decline of -25.91% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 129.49M and boasts a workforce of 158 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.9182, with a change in price of -0.2900. Similarly, Caribou Biosciences Inc recorded 1,365,906 in trading volume during the last 100 days, posting a change of -16.86%.
CRBU’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRBU stands at 0.09. Similarly, the long-term debt-to-equity ratio is also 0.09.
CRBU Stock Stochastic Average
Today, Caribou Biosciences Inc’s raw stochastic average for the past 50 days stands at 10.70%, indicating a decline from the raw stochastic average of the last 20 days, which was 17.57%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 6.78% and 5.32% respectively.
